Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab plus PD-1 inhibitor and chemotherapy in HER2-positive advanced gastric/GEJ cancer (phase II)
ChiCTR2500112766Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inetetamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoints: Objective Response Rate (ORR) and Disease Control Rate (DCR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500112766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112766.